美国安进地诺单抗怎么注射？

Denosumab Injection produced by Amgen in the United States is a human immunoglobulin G2 (IgG2) monoclonal antibody with high specificity and affinity for RANKL. By combining with RANKL, the drug prevents the activation of the RANK signaling pathway of osteoclasts, breaking the "vicious cycle" of cancer bone metastasis, thereby achieving the purpose of inhibiting tumor growth and reducing bone destruction.

In May 2019, denosumab was approved by the NMPA for the treatment of giant cell tumor of bone that is unresectable or in which surgical resection may result in severe functional disability, including adults and skeletally mature patients (defined as at least 1 mature long bone and body weight ≥45 kg) of adolescent patients. In June 2020, denosumab was approved by the NMPA for the treatment of osteoporosis in postmenopausal women with a high risk of fractures. The trade name is Proliz, making it the first and currently the only anti-RANKL monoclonal antibody drug for the treatment of osteoporosis in China.

How to inject Amgen denosumab in the United States?

Amgen denosumab in the United States can only be administered by subcutaneous injection, not intravenous infusion, intramuscular infusion, or intradermal injection. Denosumab for bone metastases from solid tumors: 120 mg subcutaneously injected every 4 weeks into the upper arm, thigh, or abdomen.

Denosumab for giant cell tumor of bone: 120 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. Administer calcium and vitamin D appropriately to prevent hypocalcemia.

For malignant hypercalcemia: 20 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

Recommended related hot articles: /newsDetail/85805.html